Legislative Oversight Of Device Third-Party Review Likely, Staffers Tell FDLI
This article was originally published in The Gray Sheet
Executive Summary
Broader support on Capitol Hill to modify FDA's third-party review program in a way that would encourage greater utilization may hinge on members of Congress backing away from the larger issue of privatizing the agency.
You may also be interested in...
CDRH Open To Third-Party Review Of 510(k)s With Clinical Data
CDRH leadership would not oppose a legislative amendment to allow third parties to review 510(k) applications that rely on clinical data, according to center director David Feigal.
CDRH Open To Third-Party Review Of 510(k)s With Clinical Data
CDRH leadership would not oppose a legislative amendment to allow third parties to review 510(k) applications that rely on clinical data, according to center director David Feigal.
CDRH Is Lead Center For Ten Combination Product Reviews In FY 2000
FDA's Center for Devices and Radiological Health was the lead center in ten reviews conducted during FY 2000 on combination products in which the area of jurisdiction was not clearcut.